TSX runs higher on rate cut expectations
DUBLIN - Investment firm Citadel Group has disclosed a 1.54% ownership position in Mural Oncology plc, according to a regulatory filing published Thursday.
The disclosure, made under Irish Takeover Panel rules, reveals Citadel holds interests in 268,223 shares representing 1.54% of Mural Oncology’s common stock. This includes 240,223 shares owned and controlled directly, plus additional interests through stock-settled derivatives.
The filing also shows Citadel maintains short positions equivalent to 1.24% of the company’s shares, primarily through stock-settled derivatives including options.
According to the disclosure, Citadel conducted several transactions in Mural Oncology shares on August 27, including multiple purchases at prices ranging from $2.06 to $2.07 per share, and several sales at similar price points.
The investment firm’s options portfolio includes various positions with expiration dates extending from September 2025 through January 2027, with strike prices ranging from $2.50 to $7.50.
Mural Oncology, an Irish-based biopharmaceutical company, trades under the ISIN code IE000LK2BOB4. The stock’s current trading activity suggests a market valuation significantly below the strike prices of some of Citadel’s longer-dated call options.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires public disclosure when an entity’s interest in a company reaches or exceeds 1% during an offer period.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.